Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic
News Jan 19, 2009
Rosetta Genomics Ltd. and collaborators have unveiled initial data relating to the company's colorectal cancer screening diagnostics test, miRscreen™ colon, which is based on a simple blood draw, and is expected to be released next year.
The company's scientists and collaborators have identified microRNA biomarkers in serum, which have the potential to accurately differentiate colorectal cancer patients from healthy individuals. The data is being presented at the ASCO 2009 Gastrointestinal Cancers Symposium, in San Francisco.
"The initial data presented by Rosetta is very significant" said Aaron Ciechanover, Nobel laureate and chairman of Rosetta's scientific advisory board. "Rosetta's scientists and their collaborators, have for the first time, identified in serum, potential microRNA biomarkers of colorectal cancer. If treated early, 90% of colon cancer patients survive. The humane, medical, and financial impact of an effective, non-invasive colon cancer screening test can not be overstated."
The company, together with collaborators, has shown that two microRNA biomarkers, obtained from a simple blood draw, identified colon cancer patients from healthy individuals with 91% sensitivity and 72% specificity.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE